Upgrade to SI Premium - Free Trial

Sarepta Therapeutics (SRPT)

16.66 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/5/26)

Latest Headlines

Form S-8 Sarepta Therapeutics, June 4, 2026 4:56 PM - SEC Filing Form 8-K Sarepta Therapeutics, For: Jun 04 June 4, 2026 4:30 PM - SEC Filing Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion June 3, 2026 8:30 AM - StreetInsider Sarepta Therapeutics to Participate in Upcoming Investor Conferences June 1, 2026 4:30 PM - BizWire Sarepta Therapeutics (SRPT) PT Lowered to $19 at Evercore ISI May 15, 2026 7:15 AM - StreetInsider Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference May 13, 2026 4:30 PM - BizWire Form 13F-HR Sarepta Therapeutics, For: Mar 31 May 13, 2026 4:23 PM - SEC Filing Sarepta Therapeutics (SRPT) Tops Q1 EPS by 217c May 6, 2026 4:46 PM - StreetInsider Form 8-K Sarepta Therapeutics, For: May 06 May 6, 2026 4:11 PM - SEC Filing Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments May 6, 2026 4:05 PM - BizWire Form 10-Q Sarepta Therapeutics, For: Mar 31 May 6, 2026 4:02 PM - SEC Filing Form SCHEDULE 13G Sarepta Therapeutics, Filed by: VANGUARD CAPITAL MANAGEMENT LLC April 30, 2026 1:10 PM - SEC Filing Form SCHEDULE 13G Sarepta Therapeutics, Filed by: VANGUARD PORTFOLIO MANAGEMENT LLC April 29, 2026 3:14 PM - SEC Filing Form ARS Sarepta Therapeutics, For: Dec 31 April 24, 2026 4:22 PM - SEC Filing Form DEFA14A Sarepta Therapeutics, April 24, 2026 4:11 PM - SEC Filing Form DEF 14A Sarepta Therapeutics, For: Jun 04 April 24, 2026 4:11 PM - SEC Filing Sarepta Therapeutics to Announce First Quarter 2026 Financial Results April 22, 2026 8:30 AM - BizWire When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech April 20, 2026 8:30 AM - Globe NewsWire H.C. Wainwright Reiterates Sell Rating on Sarepta Therapeutics (SRPT) April 17, 2026 6:46 AM - StreetInsider Sarepta Therapeutics (SRPT) PT Raised to $20 at Evercore ISI April 13, 2026 10:11 AM - StreetInsider Sarepta Therapeutics (SRPT) PT Raised to $19 at RBC Capital April 7, 2026 9:03 AM - StreetInsider Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 31, 2026 4:05 PM - BizWire This stock's bull case is 'clearly stronger today than yesterday': analyst March 27, 2026 7:00 PM - StreetInsider Form SCHEDULE 13G/A Sarepta Therapeutics, Filed by: VANGUARD GROUP INC March 27, 2026 1:00 PM - SEC Filing Mizuho Reiterates Outperform Rating on Sarepta Therapeutics (SRPT) March 26, 2026 6:39 AM - StreetInsider Sarepta Therapeutics (SRPT) PT Raised to $13 at Citi March 26, 2026 5:01 AM - StreetInsider Barclays calls Sarepta Therapeutics (SRPT) data 'encouraging,' reiterates Equalweight rating March 25, 2026 4:04 PM - StreetInsider Sarepta Therapeutics (SRPT) PT Raised to $25 at Morgan Stanley March 25, 2026 3:05 PM - StreetInsider BofA Securities stays Underperform on Sarepta Therapeutics (SRPT): data update 'directionally positive' March 25, 2026 3:02 PM - StreetInsider Mizuho on Sarepta Therapeutics (SRPT): data de-risks siRNA platform, supports BIC potential March 25, 2026 10:46 AM - StreetInsider Wolfe Research stays Peerperform on Sarepta Therapeutics (SRPT) as data boosts RNA-focused narrative March 25, 2026 10:43 AM - StreetInsider Leerink Partners on Sarepta Therapeutics (SRPT): siRNA data 'a bit of a mixed bag' March 25, 2026 10:33 AM - StreetInsider Jefferies sees '+15-30% stock move' for Sarepta Therapeutics (SRPT) following data March 25, 2026 10:32 AM - StreetInsider Sarepta shares early clinical data from siRNA treatments for rare diseases March 25, 2026 8:05 AM - StreetInsider Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 March 25, 2026 8:05 AM - BizWire Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 March 24, 2026 4:05 PM - BizWire BofA Securities on Sarepta Therapeutics (SRPT): sNDAs 'positive first step' but regulatory risk continues March 19, 2026 11:11 AM - StreetInsider Jefferies: Sarepta (SRPT) sNDA filings to set stage for 25% stock move on FDA decision March 19, 2026 10:57 AM - StreetInsider Sarepta plans regulatory submissions for two Duchenne drugs by April 2026 March 19, 2026 8:30 AM - StreetInsider Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53® March 19, 2026 8:30 AM - BizWire Cantor Fitzgerald Reiterates Neutral Rating on Sarepta Therapeutics (SRPT) March 17, 2026 7:37 AM - StreetInsider Sarepta begins enrollment for enhanced safety protocol in gene therapy study March 16, 2026 8:34 AM - StreetInsider Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duch March 16, 2026 8:33 AM - BizWire Form 4 Sarepta Therapeutics, For: Mar 11 Filed by: Estepan Ian Michael March 13, 2026 8:09 PM - SEC Filing Form 4 Sarepta Therapeutics, For: Mar 11 Filed by: Wong Ryan Ho-Yan March 13, 2026 8:07 PM - SEC Filing Form 4 Sarepta Therapeutics, For: Mar 11 Filed by: Rodino-Klapac Louise March 13, 2026 8:05 PM - SEC Filing Form 4 Sarepta Therapeutics, For: Mar 12 Filed by: Mayo Stephen March 13, 2026 8:03 PM - SEC Filing Form 4 Sarepta Therapeutics, For: Mar 11 Filed by: Rothfuss Cristin March 13, 2026 8:01 PM - SEC Filing Sarepta Therapeutics (SRPT) PT Raised to $31 at Mizuho March 12, 2026 5:06 PM - StreetInsider Form 144 Sarepta Therapeutics, Filed by: Mayo Stephen March 12, 2026 4:27 PM - SEC Filing Form 4 Sarepta Therapeutics, For: Mar 09 Filed by: Wong Ryan Ho-Yan March 11, 2026 8:08 PM - SEC Filing Form 4 Sarepta Therapeutics, For: Mar 09 Filed by: Rothfuss Cristin March 11, 2026 8:07 PM - SEC Filing Form 4 Sarepta Therapeutics, For: Mar 09 Filed by: Rodino-Klapac Louise March 11, 2026 8:04 PM - SEC Filing Form 4 Sarepta Therapeutics, For: Mar 09 Filed by: Estepan Ian Michael March 11, 2026 8:01 PM - SEC Filing Sarepta Therapeutics (SRPT) PT Raised to $9 at Citi March 10, 2026 6:35 AM - StreetInsider Jefferies Reiterates Buy Rating on Sarepta Therapeutics (SRPT) following MDA conference 2026 March 9, 2026 3:22 PM - StreetInsider Full Article List